Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM195902192600807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Usefulness of mid-regional pro-adrenomedullin for stratifying risk in emergency department patients with solid tumors attended for febrile neutropenia secondary to chemotherapy.
Emergencias
December 2024
Servicio de Análisis Clínicos, Hospital Universitario Santa Lucía, Cartagena, Murcia, España.
Objective: To analyze the usefulness of mean mid-regional pro-adrenomedullin (MR-proADM) level to stratify risk in emergency department patients with solid tumors attended for febrile neutropenia after chemotherapy. To compare risk prediction with MR-proADM to that of conventional biomarkers and scores on the Multinational Association for Supportive Care in Cancer (MASCC) score.
Methods: Prospective observational cohort study enrolling patients with solid tumors who developed febrile neutropenia after chemotherapy.
Prognostic impact and risk factors of severe neutropenia in the early phase of treatment with trifluridine-tipiracil for metastatic colorectal cancer patients: a single-center retrospective study.
Int J Colorectal Dis
January 2025
Department of Surgery, Japan Community Healthcare Organization Tokuyama Central Hospital, 1-1 Koda-Cho, Shunan, Yamaguchi, 745-0822, Japan.
Purpose: We aimed to identify the risk factors for severe neutropenia in the early phase of trifluridine-tipiracil (FTD/TPI) treatment, and their impact on overall survival (OS).
Methods: This single-center retrospective study included patients with unresectable metastatic colorectal cancer who were treated with FTD/TPI. The primary endpoint was OS, and the secondary endpoint was severe neutropenia during the first and second cycles of FTD/TPI.
Hematological toxicity assessment in breast cancer patients receiving paclitaxel: Retrospective study and single center experience.
Pak J Pharm Sci
January 2025
Clinical Pharmacy Department, Hiwa Cancer Hospital, Sulaymaniyah, Iraq.
Hematological toxicity is a predominant concern encountered during cancer treatment. Regular blood tests and follow-up are crucial for cancer patients. The objective of this study was to evaluate and compare the hematological toxicities seen by breast cancer patients who were administered paclitaxel during treatment cycles.
View Article and Find Full Text PDFEffects of Metamizole, 4-Methylaminoantipyrine, and 4-Aminoantipyrine on LX-2 Liver Cell Line Viability and Apoptosis.
Molecules
December 2024
Department of Preclinical Sciences, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania.
Metamizole (dipyrone) is a non-opioid analgesic widely used in human and veterinary medicine, despite ongoing concerns about its safety due to risks such as agranulocytosis and potential hepatotoxicity. This study investigates the cytotoxic (MTT assay) and pro-apoptotic effects of metamizole and its primary metabolites, 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA), on the LX-2 liver cell line. These metabolites are implicated in both the therapeutic and adverse effects of the drug.
View Article and Find Full Text PDFHyperthyroidism crisis and complex pancytopenia: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Endocrinology, First Affiliated Hospital of Army Medical University, Chongqing 400038.
Antithyroid drugs can cause neutropenia or agranulocytosis, rarely pancytopenia in hyperthyroidism therapy. The treatment is difficult and lethality is high when granulocytopenia or pancytopenia combined with hyperthyroidism crisis. First Affiliated Hospital of Army Medical University treated a patient who had pancytopenia caused by methimazole with systemic lupus erythematosus, secondary hyperthyroidism crisis and agranulocytosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!